We’re all for more choice to help Australians manage diabetes – it is our #1 priority

13 March 2019 

pixel pixel

 

Recognising the need to provide more choice for Australians to manage their diabetes, the Federal Government’s November 2018 expanded funding announcement included FreeStyle Libre for the first time. The Federal Government recently reiterated their intent to include the FreeStyle Libre flash glucose monitoring system on the list of products subsidised under the expanded CGM subsidy scheme for new glucose monitoring devices. 

We couldn’t agree more - our discussions with the Federal Government over the past two years have always been focused on providing more choice for Australians to manage their diabetes, with FreeStyle Libre's revolutionary technology. We also look forward to the Federal Government initiating the next steps towards subsidisation of FreeStyle Libre on the NDSS, outside of the expanded CGM subsidy funding.

We have provided exhaustive data and supporting material to support our submission in Australia - years of clinical and real-world evidence show that when individuals living with diabetes use Abbott’s Flash Glucose Monitoring technology, they have both short and long-term health benefits.

While the final decision now rests with the Federal Government, we want to reassure you that equitable and affordable access of FreeStyle Libre for Australians is our number one priority. 

FreeStyle Libre has been reviewed for supply by the Therapeutic Goods Administration (TGA) Australia and is registered with the Australian Registry of Therapeutic Goods (ARTG). It has been available for use in Australia since June 2016.  

FreeStyle Libre is used by over 1 million people globally across 46 countries, with subsidisation available in 33 countries.  Australia was among the first countries outside of Europe to introduce FreeStyle Libre and we are doing everything we can to have Australia soon join this list of subsidised countries.

 

Thank you for your ongoing support, you are our inspiration!

 

Bolinder J,et al.Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes a multicentre, non-masked, randomised controlled trial. The Lancet 2016.

Aijan, R., Insights from Real World Use of Flash Continuous Glucose Monitoring (2018, June). Symposium conducted at the conference for American Diabetes Association 78th Scientific Sessions, Orlando, FL., USA